

# Japanese Pharmacopoeial Forum

Vol. 32 No. 1

March 2023

## Contents

---

### Revision Drafts

---

#### Revision Drafts for Second Supplement to JP 18

1. General Tests, Processes and Apparatus	
(1) Revision	
2.46 Residual Solvents	352
9.41 Reagents, Test Solutions	360
2. Official Monographs	
(1) Addition	
Aripiprazole	360
Febuxostat	362
Febuxostat Tablets	364
Gefitinib Tablets	366
Goserelin Acetate	367
Lornoxicam	369
Lornoxicam Tablets	372
Oxaliplatin	374
Oxaliplatin Injection	377
Tolvaptan	379
Tolvaptan Tablets	381
(2) Revision	
Low Substituted Hydroxypropylcellulose	382
Hypromellose	383
Methylcellulose	384
3. Official Monographs – Crude Drugs	
(1) Addition	
Shin'iseihaito Extract	384
(2) Revision	
Gentian	387
Powdered Gentian	387
Ophiopogon Root	387
Uncaria Hook	388
Yokukansankachimpihange Extract	388
4. Infrared Reference Spectra	
Febuxostat	389
Lornoxicam	390
Oxaliplatin	390
Tolvaptan	390

5. Ultraviolet-visible Reference Spectra	
Febuxostat	391
Lornoxicam	391
Oxaliplatin	391
Tolvaptan	392
6. General Information	
(1) Addition	
Analyses of Size and Morphology of Nanoparticles by Atomic Force Microscope <G1-9-182>	392
Evaluation Method of Insoluble Particulate Matter in Biotechnological Products (Biopharmaceuticals) Drug Substances/Drug Products by Flow Imaging Method <G3-17-182>	395
Flow Cytometry <G3-16-182>	398

#### Revision and new general information drafts concerning balances

1. General Tests, Processes and Apparatus	
(1) Revision	
9.62 Measuring Instruments, Appliances	401
2. General Information	
(1) Addition	
Calibration, Inspection, and Weight of a weighing instrument (balance) <G1-7-182>	402
Concept of Weighing in the Japanese Pharmacopoeia <G1-6-182>	403
Installation Environment, Basic Handling Method, and Precautions for Weighing of a Balance <G1-8-182>	405

#### Revision of the description of crude drugs (addition of the sentence, “calculated on the basis of the content obtained by qNMR”, to taken amount ( $M_s$ ) in the Assay) for listed articles (official monographs)

---

### Useful Information

---

Briefing on General Test and General Information related to Balances	408
--	-----

---

**Pharmacopoeial Harmonization**

---

1. Stage 2 (Official Inquiry Stage Draft)	
(1) Monographs	
1) Revision	
① Corn Starch	197
2. Harmonized Document)	
(1) Tests	
1) Revision	
① Bulk density of powders (Revision 4)	200
② Peptide Mapping (Revision 1)	207
③ Powder flow (Revision 1)	225
(2) Monographs	
1) Correction	
① Carboxymethylcellulose Calcium (Correction 1)	233
② Hydroxypropylcellulose, Low Substituted (Correction 3)	238
③ Hypromellose (Correction 1)	243
④ Methylcellulose (Correction 1)	250
⑤ Lactose, Anhydrous (Correction 2)	257
⑥ Lactose, Monohydrate (Correction 2)	263
2) Correction of sign-off coversheet	
① Calcium Disodium Edetate	267
② Dibasic Calcium Phosphate	269
③ Anhydrous Dibasic Calcium Phosphate	271
④ Croscarmellose Sodium	273
⑤ Cellulose, Microcrystalline	275
⑥ Cellulose, Powdered	277
⑦ Cellulose Acetate Phthalate	279
⑧ Citric Acid Anhydrous	281

⑨ Citric Acid Monohydrate	283
⑩ Crospovidone	285
⑪ Ethylcellulose	287
⑫ Hydroxyethylcellulose	289
⑬ Hydroxypropylcellulose	291
⑭ Hypromellose Phthalate	293
⑮ Magnesium Stearate	295
⑯ Methyl Parahydroxybenzoate	297
⑰ Petrolatum	299
⑱ White Petrolatum	301
⑲ Polysorbate 80	303
⑳ Povidone	305
㉑ Sodium Chloride	308
㉒ Sodium Starch Glycolate	310
㉓ Stearic Acid	312
㉔ Ethyl Parahydroxybenzoate	314
㉕ Propyl Parahydroxybenzoate	316
㉖ Butyl Parahydroxybenzoate	318
㉗ Carmellose	320
㉘ Copovidone	322
㉙ Gelatin	324
㉚ Glucose Anhydrous/Monohydrate	326
㉛ Mannitol	328
㉜ Isomalt	330

---

**Reference Standards**

---

PMRJ Reference Standards	Ordering
Information for Foreign Users	410

Publishing Schedule (Vol.32, No.2): June 2023
---